ArticleFrontiers in pharmacology2026
GPR55 deletion increases anxiety- and depression-like behaviors and modifies amygdalar GABA
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: GPR55 has attracted attention for its anti-inflammatory, neuroprotective, and neurotransmitter-modulating properties, suggesting a role in mood regulation. Here, we aimed to clarify the contribution of GPR55 to emotional responses. Methods: Male and female GPR55 knockout (GPR55KO) and wild-type (WT) C57BL/6J mice were evaluated in the light-dark box, elevated plus maze, social interaction and tail suspension tests. Gene expression of the GABA Results: GPR55 deletion increased anxiety- and depressive-like behaviors across all the behavioral paradigms evaluated. GABA Discussion: Together, these findings indicate that loss of GPR55 heightens emotional vulnerability and alters specific GABAergic markers in the AMY while preserving HPA axis-related transcriptional response to acute stress. These results support GPR55 as a potential target for the modulation of anxiety- and depression-related states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.